Group 1 - The company, Hunan Hansen Pharmaceutical Co., Ltd., will participate in the "2025 Hunan Listed Companies Investor Online Collective Reception Day and Semi-Annual Performance Briefing" event [1] - The event is organized by the China Securities Regulatory Commission Hunan Regulatory Bureau, Hunan Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [1] - The online event will take place on September 19, 2025, from 14:00 to 17:00, allowing investors to engage through various platforms [1] Group 2 - The company's board secretary and securities affairs representative will interact with investors through an online Q&A format [1] - Investors are encouraged to actively participate in the event [1]

证券代码：002412 证券简称：汉森制药 公告编号：2025-019 湖南汉森制药股份有限公司 湖南汉森制药股份有限公司 董事会 2025 年 9 月 12 日 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与广大投资者的互动交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的"资本聚三湘 楚光耀新程—— 2025 年湖南辖区上市公司投资者网上集体接待日暨半年度业绩说明会"活动， 现将有关事项公告如下： 本次活动将采取网络远程的方式举行，投资者可以登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载"全景路演"APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日(星期五)14:00-17:00。届时 公司董事会秘书、证券事务代表将通过网络在线问答互动的形式，就投资者关心 的问题进行沟通与交流，欢迎广 ...

Core Viewpoint - Hansen Pharmaceutical has commenced the production and sale of 10mg empagliflozin tablets, which are indicated for the treatment of type 2 diabetes and symptomatic chronic heart failure in adults, aimed at reducing the risk of hospitalization due to heart failure. The impact of this product on the company's performance in the second half of the year remains uncertain [1] Group 1 - The 10mg empagliflozin tablets are now available for sale [1] - The product is intended for two specific medical conditions: type 2 diabetes and symptomatic chronic heart failure [1] - The company has not provided clarity on how this product will affect its financial performance in the latter half of the year [1]

Group 1 - The company Hansen Pharmaceutical reported that as of August 29, 2025, the total number of shareholders, including credit accounts, is 23,580 [2]

Core Insights - Hansen Pharmaceutical (002412) reported that as of August 29, 2025, the total number of shareholders, including those with credit accounts, is 23,580 [1] Company Summary - Hansen Pharmaceutical has engaged with investors through an interactive platform, providing updates on shareholder statistics [1] - The company is actively monitoring its shareholder base, indicating a focus on investor relations and transparency [1]

Group 1 - The company, Hansen Pharmaceutical, has confirmed that its product, Si Mo Tang Oral Liquid, has been selected for procurement in multiple projects, including the Beijing-Tianjin-Hebei "3+N" alliance and the fourth batch of centralized procurement in Fujian [2] - The product has also received selected qualification in the fifth round of drug centralized procurement in Jiangsu Province and has limited procurement qualifications in the Guangdong alliance for Jin Lianhua and other traditional Chinese medicine projects [2]

Group 1 - The core viewpoint of the news is that Hansen Pharmaceutical experienced a decline in stock price and significant financing activity on August 29, with a net financing outflow of 475.93 million yuan [1] - On August 29, Hansen Pharmaceutical's financing buy-in amounted to 9.87 million yuan, while the financing repayment was 14.63 million yuan, resulting in a total financing balance of 142 million yuan, which represents 4.19% of its market capitalization [1] - The company has a high financing balance, exceeding the 50th percentile level over the past year, indicating a relatively elevated financing position [1] Group 2 - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The main revenue sources for Hansen Pharmaceutical include Si Mo Tang oral liquid (54.81%), Tian Ma Xing Nao capsules (23.38%), and other products, with a total revenue of 5.09 billion yuan for the first half of 2025, reflecting a year-on-year growth of 5.91% [2] - The net profit attributable to the parent company for the same period was 68.54 million yuan, showing a year-on-year decrease of 31.80% [2] Group 3 - Since its A-share listing, Hansen Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3]

Core Viewpoint - Hansen Pharmaceutical experienced a decline of 4.18% in stock price on August 27, with a trading volume of 131 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On August 27, Hansen Pharmaceutical had a financing buy-in amount of 15.20 million yuan and a financing repayment of 15.99 million yuan, resulting in a net financing buy of -0.797 million yuan [1] - The total financing and securities balance for Hansen Pharmaceutical as of August 27 is 144 million yuan, which accounts for 4.30% of its circulating market value, indicating a relatively high financing level compared to the past year [1] - The company had no short-selling activity on August 27, with a short-selling balance of 0.00 shares, suggesting a lack of bearish sentiment among investors [1] Company Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang City, Hunan Province, and specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2] - The company's main revenue sources include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and other products, with the top three products contributing significantly to total revenue [2] - As of July 31, the number of shareholders increased by 1.15% to 24,400, while the average circulating shares per person decreased by 1.13% to 20,388 shares [2] Financial Performance - For the first half of 2025, Hansen Pharmaceutical reported a revenue of 509 million yuan, reflecting a year-on-year growth of 5.91%, while the net profit attributable to shareholders decreased by 31.80% to 68.54 million yuan [2] - The company has distributed a total of 485 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]

Core Insights - Hansen Pharmaceutical (002412) reported a revenue increase but a decline in net profit for the first half of 2025, with total revenue reaching 509 million yuan, up 5.91% year-on-year, while net profit dropped by 31.8% to 68.54 million yuan [1] Financial Performance - Total revenue for Q2 2025 was 240 million yuan, reflecting a 5.81% increase year-on-year, while net profit for the same quarter rose by 35.64% to 57.28 million yuan [1] - Gross margin improved to 76.78%, up 2.91% year-on-year, while net margin decreased to 13.47%, down 35.61% [1] - Total operating expenses (selling, administrative, and financial) amounted to 227 million yuan, accounting for 44.62% of revenue, a decrease of 6.5% year-on-year [1] - Earnings per share (EPS) fell to 0.14 yuan, down 31.8% year-on-year, while operating cash flow per share increased significantly by 155.49% to 0.22 yuan [1] Balance Sheet Changes - Cash and cash equivalents increased by 30.64% to 144 million yuan, while accounts receivable decreased by 2.34% to 313 million yuan [1] - Interest-bearing debt decreased by 25.60% to 67.34 million yuan [1] Variations in Financial Items - Contract liabilities decreased by 54.37% due to a reduction in cash received related to sales contracts [2] - Prepayments decreased by 40.71% as previous year-end payments for R&D and raw materials were completed [2] - Accounts payable decreased by 39.78% due to increased payments for materials [2] - Income tax expenses increased by 85.04%, reflecting a rise in corporate income tax [3] Cash Flow Analysis - Net cash flow from operating activities increased by 155.49% due to higher cash receipts from sales [4] - Net cash flow from investing activities decreased significantly by 410.22% due to increased cash outflows for bank wealth management products [4] - Net cash flow from financing activities decreased by 121.27% as bank borrowings were reduced [4] Business Evaluation - The company's return on invested capital (ROIC) was 10.19%, indicating average capital returns, with a historical median ROIC of 8.4% over the past decade [5] - The business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers of this performance [5] Accounts Receivable Concerns - The accounts receivable situation is noteworthy, with accounts receivable to profit ratio reaching 142.34% [6]

Group 1 - The core point of the announcement is that Hunan Hansen Pharmaceutical Co., Ltd. has received notification from its controlling shareholder, Hainan Hansen Holdings (Limited Partnership), regarding the release of a portion of its pledged shares [1] - As of the announcement date, the controlling shareholder's pledged shares do not pose a risk of forced liquidation and will not lead to a change in the company's actual control [1] - The company will continue to monitor the subsequent developments regarding the controlling shareholder's share pledges and will fulfill its information disclosure obligations as required [1] Group 2 - The announcement includes a reference to the share pledge registration certificate and details from the China Securities Depository and Clearing Corporation regarding securities pledges and judicial freezes [2]